First pediatric trial tests promising cancer pill for kids Who've run out of options
NCT ID NCT02909777
Summary
This early-stage study tested a new oral medication called CUDC-907 in children and young adults whose cancers had returned or stopped responding to standard treatments. The main goals were to check for side effects and find the safest dose for children, since this drug had only been tested in adults before. Researchers also wanted to see if the drug showed any signs of helping control tumors like neuroblastoma, lymphoma, and brain tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Texas Children's, Baylor College of Medicine
Houston, Texas, 77030, United States
-
University of California, San Francisco, Benioff Children's Hospital
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.